These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 20640541)

  • 1. Rituximab in immune thrombocytopenia: transient responses, low rate of sustained remissions and poor response to further therapy in refractory patients.
    Aleem A; Alaskar AS; Algahtani F; Rather M; Almahayni MH; Al-Momen A
    Int J Hematol; 2010 Sep; 92(2):283-8. PubMed ID: 20640541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical therapeutic efficacy of rituximab for relapsed and refractory idiopathic thrombocytopenic purpura].
    Zhou LY; Zhang Z; Song LX; Gzhang X; Su JY; Li X; Chang CK
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):941-4. PubMed ID: 22931660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
    Schweizer C; Reu FJ; Ho AD; Hensel M
    Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The efficacy of rituximab in patients with splenectomized refractory chronic idiopathic thrombocythopenic purpura.
    Pasa S; Altintas A; Cil T; Danis R; Ayyildiz O
    J Thromb Thrombolysis; 2009 Apr; 27(3):329-33. PubMed ID: 18311541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
    Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
    Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Retrospective analysis of rituximab therapy and splenectomy in childhood chronic and refractory immune thrombocytopenic purpura.
    Ay Y; Karapinar TH; Oymak Y; Toret E; Demirag B; Ince D; Ozcan E; Moueminoglou N; Koker SA; Vergin C
    Blood Coagul Fibrinolysis; 2016 Jun; 27(4):431-5. PubMed ID: 26656905
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.
    Stasi R; Pagano A; Stipa E; Amadori S
    Blood; 2001 Aug; 98(4):952-7. PubMed ID: 11493438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is splenectomy necessary for immune thrombocytopenic purpura? The role of rituximab in patients with corticosteroid resistance in a single-center experience.
    Zhang C; Liu HF; Chen XH; Gao L; Gao L; Liu Y; Kong PY; Sun AH; Zhang X
    Clin Ther; 2014 Mar; 36(3):385-8. PubMed ID: 24594069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of children with refractory immune thrombocytopenia treated with rituximab.
    Matsubara K; Takahashi Y; Hayakawa A; Tanaka F; Nakadate H; Sakai M; Maeda N; Oka T; Ishii E; Bessho F; Morimoto T; Goto H; Hashii Y; Hatakeyama N; Shirahata A; Imaizumi M
    Int J Hematol; 2014 Apr; 99(4):429-36. PubMed ID: 24609717
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab.
    Zaja F; Marin L; Chiozzotto M; Puglisi S; Volpetti S; Fanin R
    Am J Hematol; 2012 Mar; 87(3):321-3. PubMed ID: 22190262
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab: a pilot study.
    Giagounidis AA; Anhuf J; Schneider P; Germing U; Söhngen D; Quabeck K; Aul C
    Eur J Haematol; 2002 Aug; 69(2):95-100. PubMed ID: 12366712
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis.
    Garcia-Chavez J; Majluf-Cruz A; Montiel-Cervantes L; Esparza MG; Vela-Ojeda J;
    Ann Hematol; 2007 Dec; 86(12):871-7. PubMed ID: 17874322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rituximab for the treatment of acute refractory ITP.
    Kim SG; Whyte D; Pashankar FD
    J Pediatr Hematol Oncol; 2014 Apr; 36(3):e149-51. PubMed ID: 23669737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia.
    Heidel F; Lipka DB; von Auer C; Huber C; Scharrer I; Hess G
    Thromb Haemost; 2007 Feb; 97(2):228-33. PubMed ID: 17264951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rituximab efficacy and safety in adult splenectomy candidates with chronic immune thrombocytopenic purpura: results of a prospective multicenter phase 2 study.
    Godeau B; Porcher R; Fain O; Lefrère F; Fenaux P; Cheze S; Vekhoff A; Chauveheid MP; Stirnemann J; Galicier L; Bourgeois E; Haiat S; Varet B; Leporrier M; Papo T; Khellaf M; Michel M; Bierling P
    Blood; 2008 Aug; 112(4):999-1004. PubMed ID: 18463354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rituximab in auto-immune haemolytic anaemia and immune thrombocytopenic purpura: a Belgian retrospective multicentric study.
    Dierickx D; Verhoef G; Van Hoof A; Mineur P; Roest A; Triffet A; Kentos A; Pierre P; Boulet D; Bries G; Lê PQ; Janssens A; Delannoy A
    J Intern Med; 2009 Nov; 266(5):484-91. PubMed ID: 19549092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical study of standard dose of rituximab for the treatment of refractory primary immune thrombocytopenia].
    Zhu YC; Wang W; Zhou YH; Wang XM; Wang X; Wang YL; Sun GZ; Hou M
    Zhonghua Xue Ye Xue Za Zhi; 2011 Mar; 32(3):163-7. PubMed ID: 21535953
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment.
    Parodi E; Nobili B; Perrotta S; Rosaria Matarese SM; Russo G; Licciardello M; Zecca M; Locatelli F; Cesaro S; Bisogno G; Giordano P; De Mattia D; Ramenghia U
    Int J Hematol; 2006 Jul; 84(1):48-53. PubMed ID: 16867902
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia.
    Zaja F; Volpetti S; Chiozzotto M; Puglisi S; Isola M; Buttignol S; Fanin R
    Am J Hematol; 2012 Sep; 87(9):886-9. PubMed ID: 22718483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rituximab for immune cytopenia in adults: idiopathic thrombocytopenic purpura, autoimmune hemolytic anemia, and Evans syndrome.
    Shanafelt TD; Madueme HL; Wolf RC; Tefferi A
    Mayo Clin Proc; 2003 Nov; 78(11):1340-6. PubMed ID: 14601692
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.